Reprogrammed Interchange LLC - 30 Dec 2024 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Role
10%+ Owner
Signature
/s/ Frank Huang, Manager of Reprogrammed Interchange LLC
Issuer symbol
VOR
Transactions as of
30 Dec 2024
Net transactions value
$0
Form type
4
Filing time
02 Jan 2025, 19:42:04 UTC
Next filing
27 Aug 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VOR Common Stock Purchase +38,974,101 38,974,101 30 Dec 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VOR Warrant (Right to Buy) Purchase +48,717,626 48,717,626 30 Dec 2024 Common Stock 48,717,626 $0.8380 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Common Stock was purchased together with an accompanying Warrant to purchase 1.25 shares of Common Stock. The purchase price of the securities was $0.99425 per share and accompanying Warrant.
F2 The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
F3 The Warrants are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Warrants to the extent that such exercise would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Person, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.